Category: Allergan Inc.
Here's a look at some of the top Wall Street stories for medical device companies this week: Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Allergan cuts 1,500 jobs, faces SEC complaint; A countdown to failure for Valeant's hostile $53B Allergan takeover; GE Healthcare idles for another quarter
Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.
Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.
Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.
Here's a look at some of the top Wall Street stories for medical device companies this week: Ocular Therapeutix sets terms for IPO; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B; Exo-suit maker ReWalk files for $57.5M IPO; Intersect ENT sets terms for $65M IPO
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B
Allergan renews its battle against an unsolicited, $53 billion takeover bid by Valeant Pharmaceuticals and hedge fund ally Pershing Square Capital Management, calling for more transparency about Valeant's business.
Valeant and Pershing Square Capital Management look to replace 6 members of Allergan's board with their own slate of directors.
MASSDEVICE ON CALL — Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, asked Allergan (NYSE:AGN) shareholders today to oust Allergan's board and replace it with a slate of its own directors.